The current observations of significant alterations in serum and hepatic activin-A and follistatin following the administration of Peg-IFN-α ± RBV provide additional support for the aforementioned hypothesis and they are in agreement with our previous findings regarding the effects of Peg-INF-α based therapy on serum activin-A and follistatin during the treatment of CHC [21, 24]. Here, IFNA2 is linked to cryohydrocytosis.